Skip to main content
Equibles
SION logo

SION · Sionna Therapeutics, Inc. · Metrics

Track SION — free

Use SION with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SION.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.60 -0.20 (-5.26%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared Aug 6, 2026

The latest filing states the doubt was alleviated.

“The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. The Company believes that its existing cash, cash equivalents and marketable securities of $268.3 million as of June 30, 2026, will be sufficient to allow the Company to fund operations beyond twelve months from the date that the financial statements are issued.”
View the 10-Q filed Aug 6, 2026
Market Cap
$162.76M
Shares
45.21M
Volume · Oct 23 918.2K Avg daily vol (3M) 2.24M

SION metrics

67 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.60
Market cap
$162.76M

Price action

20 metrics
Price change (1W)
-7.5%
Price change (30D)
-31.2%
Price change (3M)
-92.1%
Price change (6M)
-90.6%
Price change (YTD)
-91.2%
Price change (1Y)
-90.9%
Trailing year
Price change (5Y)
—
52-week high
$51.04
52-week low
$3.60
Change from 52-week high
-92.9%
Change from 52-week low
+0.0%
Annualized volatility
121.2%
Annualized volatility (3M)
206.3%
Beta
1.3
RSI (14D)
24.1
Price vs SMA 50
-36.4%
Price vs SMA 200
-88.4%
Avg volume (3M)
2.24M
Relative volume
0.4
Average dollar volume
$16.20M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
45.21M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.6
reciprocal yield 163.3%
FCF yield
-46.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-59.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-09-14

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$109.49M
Net income (TTM)
−$97.38M
Trailing 12 months
Diluted EPS (TTM)
$-2.11
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-2.44
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-2.17
Operating cash flow per diluted share (TTM)
$-1.69
Free cash flow per diluted share (TTM)
$-1.70
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$1.61
Stock compensation per diluted share (TTM)
$0.46
Book value per share
$6.86

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-36.6%
Return on assets
-34.4%
Debt / equity
0.0
Current ratio
20.0
EBITDA (TTM)
—
Free cash flow (TTM)
−$76.21M
Quick ratio
20.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$63.32M
Latest balance sheet
Cash & equivalents
$63.32M
Total assets
$283.25M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$75.92M
Capital expenditures (TTM)
$291,000
R&D (TTM)
$72.04M
SG&A (TTM)
—
Stock compensation (TTM)
$20.53M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
150
13F filer change QoQ
+28
Institutional ownership
106.8%
Conviction holders (share of 13F filers)
4.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+5.0%
Holder tenure
5.4
Price vs estimated holder cost
+101.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
7.7%

Short interest

3 metrics
Short interest
8.4%
Latest settlement · 2.3 days to cover
Days to cover
2.3d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$21.84M
Insider-sentiment score
18 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 2036042 CUSIP 829401108 13F (30d) 14 filings 14 filers Visit website Investor relations